Skip to main content

Thank you for visiting You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

“Bloodless” Treatment of a Jehovah’s Witness Infant With ABO Hemolytic Disease


An ABO-incompatible term infant girl born to parents who are Jehovah’s Witnesses was admitted to our neonatal unit with a high serum bilirubin level necessitating exchange transfusion. The parents signed a request that blood should not be administered under any circumstances. However, they authorized us to apply the possible alternative treatments of orally administered D-penicillamine (300 mg/kg per day divided in three doses for 3 days), phototherapy, intravenous fluids, and recombinant human erythropoietin (200 U/kg subcutaneously on every second day for 2 weeks). Herein, we report the outcome of this baby, who was discharged from the our unit in good condition after treatment. Her physical growth and motor milestones at 14 months of age revealed no red flags for neurodevelopmental maturation. To our knowledge, this is the first case of an infant who received such a combined alternative (and “bloodless”) treatment of serious ABO hemolytic disease of the newborn.

Author information



Corresponding author

Correspondence to Lajos Lakatos MD DSc.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Lakatos, L., Csáthy, L. & Nemes, E. “Bloodless” Treatment of a Jehovah’s Witness Infant With ABO Hemolytic Disease. J Perinatol 19, 530–532 (1999).

Download citation


Quick links